Multicenter phase 1 study of ADCE-D01 in previously treated patients with advanced soft tissue sarcoma

Urokinase plasminogen activator receptor-associated protein (uPARAP) is overexpressed across soft tissue sarcoma (STS) subtypes, a family of malignancies often affecting younger patients, with a high unmet medical need, as available post-anthracycline agents achieve objective response rates (ORR) of 10% or less. ADCE-D01 is a uPARAP-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload. The multicenter phase 1 dose-escalation ADCElerate study, with first clinical data presented today at the EORTC-NCI-AACR Symposium in Barcelona (Spain), evaluated ADCE-D01 in adult patients with advanced STS and 1 or 2 prior cytotoxic therapies. Across 7 European and US sites, 47 patients with 17 STS subtypes (most frequently leiomyosarcoma [28%], synovial sarcoma [13%], and angiosarcoma [11%]), an ECOG performance status of 0-1, a median of 2 prior lines of therapy (1-4), and a median age of 54 years (21-83) were treated with a median follow-up of 3.8 months (0.1-15.0), of whom 64% remain on treatment. The initial 18 patients received weekly dosing (0.5-3.4 mg/kg); after pharmacokinetic analysis, the subsequent 29 patients received 3.4-6.6 mg/kg every two weeks (Q2W). Use of prophylactic G-CSF was mandated at doses > 3.4 mg/kg. Across all cohorts and schedules, the most common treatment-related adverse events were nausea (66%), fatigue (45%), alopecia (45%), and neutropenia (43%); leading to dose reductions in 11% of patients and discontinuation in 2%. With mandatory G-CSF, grade >3 neutropenia decreased from 40% to 14%. TRAE led to dose reduction in 9%, and no TRAE led to discontinuation or death. The Q2W maximum tolerated dose with G-CSF has not been reached yet. Of the 23 Q2W patients evaluable for response, the objective response rate was 30% (4 confirmed, 3 pending confirmation) and disease control rate was 88% at week 12. Median duration of response has not been reached; all responses were ongoing at data cutoff. The authors conclude that ADCE-D01 showed manageable safety on the Q2W schedule with G-CSF and confirmed responses with durable disease control across multiple STS subtypes. Enrollment is ongoing.